Lung ultrasound is cost-effective for early diagnosis of COVID-19 pneumonia in primary care.

Publication date: Jul 02, 2025

Chest X-rays and lung ultrasounds are extensively utilized in primary care to diagnose pneumonia, a primary clinical manifestation of COVID-19. Employing chest X-rays for the diagnostic management of suspected COVID-19 pneumonia is significantly more costly than utilizing lung ultrasound. Since the pandemic swiftly overwhelmed healthcare systems globally, identifying the most cost-effective diagnostic tools is essential to optimize resource allocation.

Open Access PDF

Concepts Keywords
Covid Chest X-ray
Early Cost analysis
Pandemic Cost-Benefit Analysis
Pneumonia COVID-19
Ultrasounds COVID-19
Early Diagnosis
General practice
Humans
Lung
Lung ultrasonography
Primary Health Care
SARS-CoV-2
Ultrasonography

Semantics

Type Source Name
disease MESH COVID-19
disease MESH pneumonia
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH infection
drug DRUGBANK Alpha-Linolenic Acid
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Gold
drug DRUGBANK Factor IX Complex (Human)
disease MESH dyspnea
disease MESH anosmia
disease MESH tic
disease IDO intervention
disease IDO process
drug DRUGBANK Water
drug DRUGBANK Trestolone
drug DRUGBANK MCC
drug DRUGBANK Esomeprazole
drug DRUGBANK Penciclovir
drug DRUGBANK Aminosalicylic Acid
disease IDO site
disease MESH Comas
drug DRUGBANK Allylestrenol
disease MESH emergency

Original Article

(Visited 11 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *